Staphylococcus aureus-Cure-Associated Antigens Elicit Type 3 Immune Memory T Cells
-
Published:2022-12-16
Issue:12
Volume:11
Page:1831
-
ISSN:2079-6382
-
Container-title:Antibiotics
-
language:en
-
Short-container-title:Antibiotics
Author:
Santos Kamila R.ORCID, Souza Fernando N.ORCID, Ramos-Sanchez Eduardo M.ORCID, Batista Camila F., Reis Luiza C.ORCID, Fotoran Wesley L.ORCID, Heinemann Marcos B.ORCID, Cunha Adriano F.ORCID, Rocha Mussya C., Faria Angélica R.ORCID, Andrade Hélida M., Cerqueira Mônica M. O. P., Gidlund MagnusORCID, Goto HiroORCID, Della Libera Alice Maria M. P.ORCID
Abstract
Background: Staphylococcus aureus is one of the most frequently major mastitis pathogens that cause clinical and subclinical mastitis worldwide. Current antimicrobial treatments are usually ineffective, and the commercially available vaccines lack proven effectiveness. The immunological response elicited by the recombinant S. aureus-cure-associated proteins phosphoglycerate kinase (PGK), enolase (ENO), and elongation factor-G (EF-G) in combination with the granulocyte-macrophage colony-stimulating factor (GM-CSF) DNA vaccination was studied in this work. Methods: Here, twenty-three C57BL/6 mice were divided into four groups and vaccinated with: G1: none (control); G2: GM-CSF DNA plasmid DNA vaccine; G3: the combination of EF-G+ENO+PGK; and G4: the combinations of EF-G+ENO+PGK proteins plus GM-CSF plasmid DNA vaccine. After 44 days, spleen cells were collected for immunophenotyping and lymphocyte proliferation evaluation by flow cytometry upon S. aureus stimulus. Results: Immunization with the three S. aureus recombinant proteins alone resulted in a higher percentage of IL-17A+ cells among CD8+ T central memory cells, as well as the highest intensity of IL-17A production by overall lymphocytes indicating that the contribution of the combined lymphocyte populations is crucial to sustaining a type 3 cell immunity environment. Conclusion: The immunization with three S. aureus-cure-associated recombinant proteins triggered type 3 immunity, which is a highly interesting path to pursue an effective bovine S. aureus mastitis vaccine.
Funder
São Paulo Research Foundation–FAPESP Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–Brasil
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference43 articles.
1. Mastitis prevention and control practices and mastitis treatment strategies associated with the comsuption of (critically important) antimicrobials o dairy herds in Flanders, Belgium;Stevens;J. Dairy Sci.,2016 2. Santos, R.P., Souza, F.N., Oliveira, A.C.D., de Souza Filho, A.F., Aizawa, J., Moreno, L.Z., da Cunha, A.F., Cortez, A., Della Libera, A.M.M.P., and Heinemann, M.B. (2020). Molecular typing and antimicrobial susceptibility profile of Staphylococcus aureus isolates recovered from bovine mastitis and nasal samples. Animals, 10. 3. Knowledge gaps and research priorities in Staphylococcus aureus mastitis control;Rainard;Transbound. Emerg. Dis.,2018 4. Gene exchange drives the ecological success of a multi-host bacterial pathogen;Richardson;Nat. Ecol. Evol.,2018 5. Campos, B., Pickering, A.C., Rocha, L.S., Aguilar, A.P., Fabres-Klein, M.H., de Oliveira Mendes, T.A., Fitzgerald, J.R., and de Oliveira Barros Ribon, A. (2022). Diversity and pathogenesis of Staphylococcus aureus from bovine mastitis: Current understanding and future perspectives. BMC Vet. Res., 18.
|
|